Investigational and unproven therapies in atopic dermatitis

Immunology and Allergy Clinics of North America

Volumn 30, Issue 3, 2010, Pages 425-439

  Ong, Peck Y ^a,b   Boguniewicz, Mark ^c  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Atopic dermatitis; Experimental therapy; Treatment

Indexed keywords

ANTIINFECTIVE AGENT; BETAMETHASONE VALERATE; CALCIPOTRIOL; CANODERM; CERAGENIN; CHEMOKINE RECEPTOR ANTAGONIST; CHLORHEXIDINE; COLECALCIFEROL; CYTOKINE RECEPTOR ANTAGONIST; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; EMOLLIENT AGENT; ERGOCALCIFEROL; IMMUNOGLOBULIN; INTERLEUKIN 31 ANTIBODY; MYCOBACTERIUM VACCINE; NALTREXONE; OLIGONUCLEOTIDE; OMALIZUMAB; OPIATE ANTAGONIST; PENTASTAPH; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIMECROLIMUS; PLACEBO; SEMAPHORIN 3A; SKIN PROTECTIVE AGENT; STAPHYLOCOCCUS VACCINE; SUPLATAST TOSYLATE; TACROLIMUS; TOXIN ANTIBODY; TRICLOSAN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; ATOPIC DERMATITIS; BACTERIAL COLONIZATION; BALNEOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMMUNICABLE DISEASE; DEVELOPING COUNTRY; DISEASE CONTROL; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG SAFETY; ECZEMA; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; MUSCLE CRAMP; NANOFABRICATION; NAUSEA; NONHUMAN; PATIENT EDUCATION; PHOTOTHERAPY; PRIORITY JOURNAL; PUVA; RECURRENCE RISK; REVIEW; SINGLE DRUG DOSE; SKIN BIOPSY; SKIN WATER LOSS; STAPHYLOCOCCAL SKIN INFECTION; VACCINIA VIRUS; VOMITING;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COMPLEMENTARY THERAPIES; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; HISTAMINE ANTAGONISTS; HUMANS; RECEPTORS, CHEMOKINE; STAPHYLOCOCCAL SKIN INFECTIONS; TH1-TH2 BALANCE; THERAPIES, INVESTIGATIONAL;

EID: 77955503411     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2010.05.002     Document Type: Review

References (93)

1. Odhiambo J.A., Williams H.C., Clayton T.O., et al. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. J Allergy Clin Immunol 2009, 124:1251-1258.
2. Faught J., Bierl C., Barton B., et al. Stress in mothers of young children with eczema. Arch Dis Child 2007, 92:683-686.
3. Brenninkmeijer E.E., Legierse C.M., Sillevis Smitt J.H., et al. The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol 2009, 26:14-22.
4. Boguniewicz M., Abramovits W., Paller A., et al. A multiple-domain framework of clinical, economic, and patient-reported outcomes for evaluating benefits of intervention in atopic dermatitis. J Drugs Dermatol 2007, 6:416-423.
5. Ellis C.N., Drake L.A., Prendergast M.M., et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002, 46:361-370.
6. Cork M.J., Danby S.G., Vasilopoulos Y., et al. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol 2009, 129:1892-1908.
7. Leung D.Y.M., Boguniewicz M., Howell M., et al. New insights into atopic dermatitis. J Clin Invest 2004, 113:651-657.
8. Boguniewicz M., Leung D.Y. Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 2010, 125:4-13.
9. Ong P., Boguniewicz M. Atopic dermatitis. Primary care: clinics in office practice 2008, 35:105-117. Elsevier, Philadelphia. R. Katial (Ed.).
10. Akdis C.A., Akdis M., Bieber T., et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. J Allergy Clin Immunol 2006, 118:152-169.
11. Charman C.R., Morris A.D., Williams H.C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000, 142:931-936.
12. Krejci-Manwaring J., Tusa M.G., Carroll C., et al. Stealth monitoring of adherence to topical medication: adherence is very poor in children with atopic dermatitis. J Am Acad Dermatol 2007, 56:211-216.
13. Zuberbier Zuberbier T., Orlow S.J., Paller A.S., et al. Patient perspectives on the management of atopic dermatitis. J Allergy Clin Immunol 2006, 118:226-232.
14. Fonacier L., Spergel J., Charlesworth E.N., et al. Report of the Topical Calcineurin Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2005, 115:1249-1253.
15. Arellano F.M., Wentworth C.E., Arana A., et al. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis. J Invest Dermatol 2007, 127:808-816.
16. Orlow S.J. Topical calcineurin inhibitors in pediatric atopic dermatitis: a critical analysis of current issues. Paediatr Drugs 2007, 9:289-299.
17. Ong P.Y. Emerging drugs for atopic dermatitis. Expert Opin Emerg Drugs 2009, 14:165-179.
18. Sugarman J.L., Parish L.C. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 2009, 8:1106-1111.
19. BuBmann C., Bieber T., Novak N. Systemic therapeutic options for severe atopic dermatitis. J Dtsch Dermatol Ges 2009, 7:205-219.
20. Gambichler T. Management of atopic dermatitis using photo(chemo)therapy. Arch Dermatol Res 2009, 301:197-203.
21. Devillers A.C., Oranje A.P. Efficacy and safety of 'wet-wrap' dressings as an intervention treatment in children with severe and/or refractory atopic dermatitis: a critical review of the literature. Br J Dermatol 2006, 154:579-585.
22. Boguniewicz M., Nicol N.H., Kelsay K., et al. A multidisciplinary approach to evaluation and treatment of atopic dermatitis. Semin Cutan Med Surg 2008, 27:117-127.
23. Loden M., Andersson A.C., Lindberg M. Improvement in skin barrier function in patients with atopic dermatitis after treatment with a moisturizing cream (Canoderm). Br J Dermatol 1999, 140:264-267.
24. Kezic S., Kemperman P.M., Koster E.S., et al. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. J Invest Dermatol 2008, 128:2117-2119.
25. Wirén K., Nohlgård C., Nyberg F., et al. Treatment with a barrier-strengthening moisturizing cream delays relapse of atopic dermatitis: a prospective and randomized controlled clinical trial. J Eur Acad Dermatol Venereol 2009, 23:1267-1272.
26. Grether-Beck S., Mühlberg K., Brenden H., et al. Bioactive molecules from the Blue Lagoon: in vitro and in vivo assessment of silica mud and microalgae extracts for their effects on skin barrier function and prevention of skin ageing. Exp Dermatol 2008, 17:771-779.
27. Schlievert P.M., Strandberg K.L., Lin Y.C., et al. Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus and its relevance to atopic dermatitis. J Allergy Clin Immunol 2010, 125:39-49.
28. Fluhr J.W., Breternitz M., Kowatzki D., et al. Silver-loaded seaweed-based cellulosic fiber improves epidermal skin physiology in atopic dermatitis: safety assessment, mode of action and controlled, randomized single-blinded exploratory in vivo study. Exp Dermatol 2009, [Epub ahead of print].
29. Lai Y., Di Nardo A., Nakatsuji T., et al. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med 2009, 15:1377-1382.
30. Huang J.T., Abrams M., Tlougan B., et al. Treatment of Staphylococcus aureus colonization in atopic dermatitis decreases disease severity. Pediatrics 2009, 123:e808-e814.
31. Wohlrab J., Jost G., Abeck D. Antiseptic efficacy of a low-dosed topical triclosan/chlorhexidine combination therapy in atopic dermatitis. Skin Pharmacol Physiol 2007, 20:71-76.
32. Tan W.P., Suresh S., Tey H.L., et al. A randomized double-blind controlled trial to compare a triclosan-containing emollient with vehicle for the treatment of atopic dermatitis. Clin Exp Dermatol 2010, 35:e109-e112.
33. Wang R., Braughton K.R., Kretschmer D., et al. Identification of novel cytolytic peptides as key virulence determinants for community-associated MRSA. Nat Med 2007, 13:1510-1514.
34. Park J., Jagasia R., Kaufmann G.F., et al. Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 2007, 14:1119-1127.
35. Otto M. Targeted immunotherapy for staphylococcal infections: focus on anti-MSCRAMM antibodies. BioDrugs 2008, 22:27-36.
36. Stranger-Jones Y.K., Bae T., Schneewind O. Vaccine assembly from surface proteins of Staphylococcus aureus. Proc Natl Acad Sci U S A 2006, 103:16942-16947.
37. Clarke S.R., Brummell K.J., Horsburgh M.J., et al. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis 2006, 193:1098-1108.
38. Weidenmaier C., Kokai-Kun J.F., Kristian S.A., et al. Role of teichoic acids in Staphylococcus aureus nasal colonization, a major risk factor in nosocomial infections. Nat Med 2004, 10:243-245.
39. Travers J.B., Kozman A., Mousdicas N., et al. Infected atopic dermatitis lesions contain pharmacologic amounts of lipoteichoic acid. J Allergy Clin Immunol 2010, 125:146-152. e1-2.
40. Buonpane R.A., Churchill H.R., Moza B., et al. Neutralization of staphylococcal enterotoxin B by soluble, high-affinity receptor antagonists. Nat Med 2007, 13:725-729.
41. Yang X., Buonpane R.A., Moza B., et al. Neutralization of multiple staphylococcal superantigens by a single-chain protein consisting of affinity-matured, variable domain repeats. J Invest Dermatol 2008, 198:344-348.
42. Vora S., Damon I., Fulginiti V., et al. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin Infect Dis 2008, 46:1555-1561.
43. Howell M.D., Gallo R.L., Boguniewicz M., et al. Cytokine milieu of atopic dermatitis skin subverts the innate immune response to vaccinia virus. Immunity 2006, 24:341-348.
44. Howell M.D., Streib J.E., Leung D.Y. Antiviral activity of human beta-defensin 3 against vaccinia virus. J Allergy Clin Immunol 2007, 119:1022-1025.
45. Savage P.B., Li C., Taotafa U., et al. Antibacterial properties of cationic steroid antibiotics. FEMS Microbiol Lett 2002, 217:1-7.
46. Ding B., Taotofa U., Orsak T., et al. Synthesis and characterization of peptide-cationic steroid antibiotic conjugates. Org Lett 2004, 6:3433-3436.
47. Howell M.D., Streib J.E., Kim B.E., et al. Ceragenins: a class of antiviral compounds to treat orthopox infections. J Invest Dermatol 2009, 129:2668-2675.
48. Lonsdorf A.S., Hwang S.T., Enk A.H. Chemokine receptors in T-cell-mediated diseases of the skin. J Invest Dermatol 2009, 129:2552-2566.
49. Ong P.Y., Ferdman R.M., Dunaway T., et al. Down-regulation of atopic dermatitis-associated serum chemokines by wet-wrap treatment: a pilot study. Ann Allergy Asthma Immunol 2008, 100:286-287.
50. Nakagami Y., Kawashima K., Yonekubo K., et al. Novel CC chemokine receptor 4 antagonist RS-1154 inhibits ovalbumin-induced ear swelling in mice. Eur J Pharmacol 2009, 624:38-44.
51. Willems L.I., Ijzerman A.P. Small molecule antagonists for chemokine CCR3 receptors. Med Res Rev 2009, [Epub ahead of print].
52. Suzuki K., Morokata T., Morihira K., et al. In vitro and in vivo characterization of a novel CCR3 antagonist, YM-344031. Biochem Biophys Res Commun 2006, 339:1217-1223.
53. Igawa K., Satoh T., Yokozeki H. A therapeutic effect of STAT6 decoy oligodeoxynucleotide ointment in atopic dermatitis: a pilot study in adults. Br J Dermatol 2009, 160:1124-1126.
54. Groves R.W., Wilbraham D., Fuller R., et al. Inhibition of IL-4 and IL-13 with an IL-4 mutein (Aeroderm) protects against flares in atopic eczema. J Invest Dermatol 2007, 127:S54.
55. Morioka T., Yamanaka K., Mori H., et al. IL-4/IL-13 antagonist DNA vaccination successfully suppresses Th2 type chronic dermatitis. Br J Dermatol 2009, 160:1172-1179.
56. Kimata H. Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Ann Allergy Asthma Immunol 1999, 82:293-295.
57. Murakami T., Yamanaka K., Tokime K., et al. Topical suplatast tosilate (IPD) ameliorates Th2 cytokine-mediated dermatitis in caspase-1 transgenic mice by downregulating interleukin-4 and interleukin-5. Br J Dermatol 2006, 155:27-32.
58. Miyachi Y., Katayama I., Furue M. Suplatast/tacrolimus combination therapy for refractory facial erythema in adult patients with atopic dermatitis: a meta-analysis study. Allergol Int 2007, 56:269-275.
59. Behshad R., Cooper K.D., Korman N.J. A retrospective case series review of the peroxisome proliferator-activated receptor ligand rosiglitazone in the treatment of atopic dermatitis. Arch Dermatol 2008, 144:84-88.
60. Staumont-Sallé D., Abboud G., Brénuchon C., et al. Peroxisome proliferator-activated receptor alpha regulates skin inflammation and humoral response in atopic dermatitis. J Allergy Clin Immunol 2008, 121:962-968.
61. Hatano Y., Man M.Q., Uchida Y., et al. Murine atopic dermatitis responds to peroxisome proliferator-activated receptors alpha and beta/delta (but not gamma) and liver X receptor activators. J Allergy Clin Immunol 2010, 125:160-169. e1-5.
62. De Vry C.G., Valdez M., Lazarov M., et al. Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J Invest Dermatol 2005, 125:473-481.
63. Takei S., Arora Y.K., Walker S.M. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993, 91:602-607.
64. Jolles S. A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. Clin Exp Dermatol 2002, 27:3-7.
65. Holgate S., Casale T., Wenzel S., et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005, 115:459-465.
66. Vigo P.G., Girgis K.R., Pfuetze B.L., et al. Efficacy of anti-IgE therapy in patients with atopic dermatitis therapy on cutaneous symptoms of AD. J Am Acad Dermatol 2006, 55:168-170.
67. Krathen R.A., Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005, 53:338-340.
68. Lane J.E., Cheyney J.M., Lane T.N., et al. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006, 54:68-72.
69. Belloni B., Ziai M., Lim A., et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007, 120:1223-1225.
70. Werfel T., Breuer K., Rueff F., et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006, 61:202-205.
71. Bussmann C., Maintz L., Hart J., et al. Clinical improvement and immunological changes in atopic dermatitis patients undergoing subcutaneous immunotherapy with a house dust mite allergoid: a pilot study. Clin Exp Allergy 2007, 37:1277-1285.
72. Pajno G.B., Caminili L., Vita D., et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007, 120:164-170.
73. Katayama I., Minatohara K., Yokozeki H., et al. Topical vitamin D3 downregulates IgE-mediated murine biphasic cutaneous reactions. Int Arch Allergy Immunol 1996, 111(1):71-76.
74. Li M., Hener P., Zhang Z., et al. Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci U S A 2006, 103:11736-11741.
75. Vähävihu K., Ylianttila L., Salmelin R., et al. Heliotherapy improves vitamin D balance and atopic dermatitis. Br J Dermatol 2008, 158:1323-1328.
76. Autio P., Komulainen P., Larni H.M. Heliotherapy in atopic dermatitis: a prospective study on climatotherapy using the SCORAD index. Acta Derm Venereol 2002, 82:436-440.
77. Sidbury R., Sullivan A.F., Thadhani R.I., et al. Randomized controlled trial of vitamin D supplementation for winter-related atopic dermatitis in Boston: a pilot study. Br J Dermatol 2008, 159:245-247.
78. Ong P.Y., Ohtake T., Brandt C., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002, 347:1151-1160.
79. Christophers E., Henseler T. Contrasting disease patterns in psoriasis and atopic dermatitis. Arch Dermatol Res 1987, 279:S48-S51.
80. Hata T.R., Kotol P., Jackson M., et al. Administration of oral vitamin D induces cathelicidin production in atopic individuals. J Allergy Clin Immunol 2008, 122:829-831.
81. Arkwright P.D., David T.J. Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J Allergy Clin Immunol 2001, 107:531-534.
82. Berth-Jones J., Arkwright P.D., Marasovic D., et al. Killed Mycobacterium vaccae suspension in children with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled trial. Clin Exp Allergy 2006, 36:1115-1121.
83. Brothers S., Asher M.I., Jaksic M., et al. Effect of a Mycobacterium vaccae derivative on paediatric atopic dermatitis: a randomized, controlled trial. Clin Exp Dermatol 2009, 34:770-775.
84. Arkwright P.D., David T.J. Effect of Mycobacterium vaccae on atopic dermatitis in children of different ages. Br J Dermatol 2003, 149:1029-1034.
85. Bigliardi P.L., Stammer H., Jost G., et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007, 56:979-988.
86. Malekzad F., Arbabi M., Mohtasham N., et al. Efficacy of oral naltrexone on pruritus in atopic eczema: a double-blind, placebo-controlled study. J Eur Acad Dermatol Venereol 2009, 23:948-950.
87. Ständer S., Böckenholt B., Schürmeyer-Horst F., et al. Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study. Acta Derm Venereol 2009, 89:45-51.
88. Sonkoly E., Muller A., Lauerma A.I., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006, 117:411-417.
89. Grimstad O., Sawanobori Y., Vestergaard C., et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: a model of atopic dermatitis. Exp Dermatol 2009, 18:35-43.
90. Tominaga M., Ogawa H., Takamori K. Decreased production of semaphorin 3A in the lesional skin of atopic dermatitis. Br J Dermatol 2008, 158:842-844.
91. Yamaguchi J., Nakamura F., Aihara M., et al. Semaphorin3A alleviates skin lesions and scratching behavior in NC/Nga mice, an atopic dermatitis model. J Invest Dermatol 2008, 128:2842-2849.
92. Tominaga M., Tengara S., Kamo A., et al. Psoralen-ultraviolet A therapy alters epidermal Sema3A and NGF levels and modulates epidermal innervation in atopic dermatitis. J Dermatol Sci 2009, 55:40-46.
93. Fallon P.G., Sasaki T., Sandilands A., et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet 2009, 41:602-608.